MDR-TB is a form of TB characterized by resistance to the two most powerful drugs in the first-line regimen, isoniazid and rifampicin[1], meaning patients have considerably reduced options for tackling the disease.

“MDR-TB occurs in patients who are infected with a drug-resistant strain of TB, or because of unsuccessful prior treatment regimens,” said Chu Naihui, director of TB department of the Beijing Chest Hospital. “MDR-TB places a significant burden on patients, and is a particular problem in China, which accounts for almost 15 percent of the world’s MDR-TB cases[2]. Due to its unique mechanism of action, SIRTURO? represents a major advancement in the fight against MDR-TB.”

Tuberculosis, and particularly MDR-TB, represents one of the world’s top health challenges, and is a serious burden and threat for China. The World Health Organization estimates that among the 1 million new TB cases in China every year, there are 70,000 cases of MDR-TB.[3].

Globally in 2015, an estimated 10.4 million people fell ill with TB, and an estimated 1.4 million people died from the disease worldwide[4]. By 2050, MDR-TB could incur more than $16 trillion in costs for governments across the world[5], making it a large and growing public health and economic threat.

To date, anti-TB regimens have been focused on drugs that were approved before the 1960s, and have included limited treatment options for patients with MDR-TB.

“Our focus now is to work together with multiple stakeholders across China to ensure appropriate use of SIRTURO? and to support efforts that will help overcome MDR-TB,” said Avery Ince MD PhD, Vice President of Medical Affairs at Xian Janssen Pharmaceutical Ltd.

SIRTURO? also represents an important tool in support of global public health efforts to tackle bacterial resistance to antibiotics. In September, world leaders used the United Nations high level meeting on antimicrobial resistance to call for a multi-sectoral approach towards tackling the issue[6], and it is in this spirit that Xian Janssen will work to introduce the medicine in China.

Appropriate use of SIRTURO? is fundamental to Xian Janssen’s efforts to overcome MDR-TB, and the company is working with partners, including those on the frontline in the battle against TB, to establish a robust access program to ensure appropriate programmatic use of SIRTURO? in China. This program will enable patients to use SIRTURO? both safely and appropriately while also reducing the likelihood of further resistant forms of TB bacteria emerging.

“Xian Janssen understands the significant unmet medical needs and challenges surrounding the treatment of MDR-TB in China, and we are committed to working with our partners to introduce and support access to SIRTURO?,” added Asgar Rangoonwala, President of Xian Janssen Pharmaceutical Ltd. “Appropriate use is an integral aspect of the introduction of new TB treatment regimens and we take very seriously our obligation to ensure that SIRTURO? provides utility for patients today and in the future.” 

About BEDAQUILINE
Bedaquiline was granted accelerated approval by the U.S. FDA in December 2012, received conditional approval in the European Union, and is registered in the Russian Federation through a partner for the Russian Federation and CIS countries, JSC Pharmstandard. In addition, bedaquiline is approved in China, Armenia, Hong Kong (China), India, New Zealand, Peru, the Philippines, South Africa, South Korea, Taiwan region, Turkmenistan and Uzbekistan. Regulatory filings have also been submitted in Bangladesh, Burundi, Colombia, Ghana, Indonesia, Kenya, Mexico, Rwanda, Tanzania, Thailand, Turkey, Uganda, and Vietnam. Pharmstandard has submitted an additional regulatory filing in Moldova.